Anti-CGRP antibodies prevented not just migraine headaches but also the warning signs, aura, and accompanying symptoms in chronic migraine responders, while also reducing anxiety and stress.
45% less stressBeyond preventing headaches, anti-CGRP antibodies reduced stress, anxiety (26.3%), and panic attacks (15%) in chronic migraine responders
What the researchers found
In 80 chronic migraine patients who responded well to anti-CGRP antibodies (erenumab, fremanezumab, or galcanezumab), the drugs prevented not just the headache but also the anticipatory and accompanying symptoms of migraine. Most patients experienced complete prevention without evidence of an attack starting and being aborted. Only 10–12.5% reported residual prodromal symptoms without headache, and 1.3–8.8% had accompanying symptoms without headache. All patients with aura reported decreased aura incidence. Additional effects included sleep changes (51.2%), increased appetite (20%), weight gain (18.8%), reduced stress (45%), reduced anxiety (26.3%), and fewer panic attacks (15%).
Why it matters
Most migraine research focuses on headache frequency and severity, but migraine is far more than a headache — it includes prodromal symptoms, aura, nausea, light sensitivity, and cognitive changes. This study shows anti-CGRP antibodies don't just suppress pain; they appear to prevent the entire migraine cascade from initiating, which tells us something fundamental about how CGRP drives the disease.
How the study worked
This was an explorative, prospective, questionnaire-based study of 80 chronic migraine patients who had achieved a sustained response to anti-CGRP antibody treatment (≥50% reduction in Migraine Disability Assessment Score and ≥30% reduction in monthly migraine days at three months). Patients completed questionnaires about prodromal symptoms, accompanying symptoms, aura, and neurological/psychiatric changes during treatment with erenumab, fremanezumab, or galcanezumab.
Who was studied
80 chronic migraine patients who responded well to anti-CGRP antibody treatment (erenumab, fremanezumab, or galcanezumab)
What this study cannot tell us
The study only included treatment responders (patients with ≥50% disability reduction), so results don't apply to non-responders. The sample size of 80 is modest. As a questionnaire-based study, it relies on patient recall. There was no placebo control group, so some improvements could reflect placebo effects or natural variation. The study did not distinguish effects between the three different antibodies.
How to read the evidence
This is a prospective observational study without a control group, limited to treatment responders. While it provides valuable real-world insights, the lack of blinding and placebo comparison limits the strength of causal conclusions.
When this study was published
Published in 2022, this study reflects the early post-approval experience with anti-CGRP antibodies. The findings remain relevant as these drugs are now widely prescribed.
The bigger picture
Anti-CGRP antibodies revolutionized migraine prevention, but most clinical trials only measured headache days. This study reveals the drugs' effects go deeper — they appear to shut down the entire migraine cascade, not just the pain phase. This has implications for understanding migraine as a whole-brain disorder driven by CGRP signaling, not just a pain condition.
Questions still open
- Do anti-CGRP antibodies prevent migraine symptoms in non-responders too, just at insufficient levels — or do non-responders have a fundamentally different migraine mechanism?
- Are the mood and sleep improvements caused by CGRP blockade directly, or are they secondary effects of having fewer migraines?
- Could the appetite and weight changes reported be a concern for long-term use?
Common questions
Do anti-CGRP drugs help with migraine symptoms beyond just the headache?
Do anti-CGRP antibodies cause weight gain?
Read the original research
Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine.
Cephalalgia : an international journal of headache, 42(13), 1323-1330
Citation
Iannone, Luigi Francesco; De Cesaris, Francesco; Ferrari, Anita; Benemei, Silvia; Fattori, Davide; Chiarugi, Alberto. (2022). Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine.. Cephalalgia : an international journal of headache, 42(13), 1323-1330. https://doi.org/10.1177/03331024221111526